APPlexus 2024 Biliary Tract Cancer

CE / CME

APPlexus Hot Topics 2024: Advances in Targeted Therapeutics for Biliary Tract Cancer

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 05, 2024

Expiration: June 04, 2025

Beth Faiman
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Caroline Kuhlman
Caroline Kuhlman, MSN, APRN-BC

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: Which of the following is TRUE regarding management of irAEs in patients treated with immune checkpoint inhibitors for BTC?

2.

Presurvey 2: Which of the following agents is an MDM2 inhibitor with an ongoing phase II study into which patients with advanced TP53-WT, MDM2-amplified BTC could be enrolled? 

3.

  • 37-yr-old female with ICC; underwent resection and 6 mo of adjuvant therapy but experiences recurrence 18 mo later

  • PD with gemcitabine + cisplatin

  • Tumor molecular profiling: FGFR2-POC1B fusion, MSS

Presurvey 3: In your current practice, which of the following treatments would you recommend for this patient?